序号股票简称PE(TTM)PE(静)市净率总市值(元)13海尔生物29.7027.482.26100.76亿行业平均 52.3447.744.60110.17亿行业中值36.9936.882.5451.28亿1九安医疗11.0211.150.87186.01亿2英科医疗 12.1013.041.08191.13亿3新华医疗14.8113.731.2194.95亿4振德医疗15.4114.530.9855.95亿5山东药玻 15.8315.881.82149.71亿6奥美医疗15.8415.531.6357.25亿7康德莱16.4816.491.3735.51亿8奥泰生物 16.9717.891.3754.11亿9九强生物17.0915.892.0984.66亿10维力医疗17.6618.352.0740.27亿11安图生物 19.1918.322.46218.80亿12三鑫医疗19.3319.343.1843.99亿 7月18日，海尔生物今日收盘31.69元，上涨1.02%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到29.70倍，创43天以来新低，总市值100.76亿元。 从行业市盈率排名来 ...

青岛海尔生物医疗股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/14 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 1 1 月 13 | 月 | 14 | 日~2026 | 年 | 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 1,636,768股 | | | | | | | 累计已回购股数占总股本比例 | 0.5148% | | | | | | | 累计已回购金额 | 52,757,057.64元 | | | | | | | 实际回购价格 ...

偏弱 趋势方向 主力成本分析 海尔生物688139 时间: 2025年6月24日星期二 40.66分综合得分 30.50 元 当日主力成本 30.11 元 5日主力成本 30.58 元 20日主力成本 31.54 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 跌停 0 次 北向资金数据 | 持股量1693.16万股 | 占流通比5.32% | | --- | --- | | 昨日净买入-51.00万股 | 昨日增仓比-0.16% | | 5日增仓比-0.757% | 20日增仓比-2.411% | 技术面分析 30.78 短期压力位 29.83 短期支撑位 31.36 中期压力位 29.65 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 暂无特殊形态 资金流数据 2025年06月24日的资金流向数据方面 | 主力资金净流入502.41万元 | | --- | | 占总成交额8% | | 超大单净流出103.97万元 | | 大单净流入606.38万元 | | 散户资金净流出115.86万 | 关联行业/概念板块 医疗器械 1.4 ...

Group 1 - The stock of Haier Biomedical (688139) has a comprehensive score of 42.72, indicating a weak performance [1] - The main cost analysis shows that the current main cost is 30.07 CNY, with a 5-day main cost of 30.55 CNY and a 20-day main cost of 31.69 CNY [1] - There have been no instances of the stock hitting the upper limit in the past year, and it has also not hit the lower limit [1] Group 2 - The short-term pressure level is at 31.36 CNY, while the short-term support level is at 30.28 CNY [2] - The stock price has broken below the short-term support level, suggesting a cautious approach in the short term [2] - The MACD indicator has formed a golden cross signal, indicating potential upward momentum for certain stocks [3]

6月18日，海尔生物今日收盘30.28元，下跌1.62%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到28.38倍，总市值96.28亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.10倍，行业中值36.43倍，海尔生物排 名第65位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13海尔生物28.3826.262.1696.28亿行业平均 49.1047.114.54105.10亿行业中值36.4336.872.3948.92亿1英科医疗9.5610.310.85151.03亿2九安医疗 10.1210.230.80170.79亿3新华医疗14.2213.181.1691.18亿4振德医疗14.6413.800.9353.16亿5康德莱 14.7414.751.2231.75亿6奥美医疗14.8614.571.5353.70亿7山东药玻15.7315.781.81148.78亿8九强生物 15.7414.641.9377.95亿9维力医疗15.7716.391.8535.96亿10奥泰生物16.0716.951.3051.26亿11安杰思 17.3817.582. ...

Economic Overview - In 2024, Shandong's GDP reached 98,565.8 billion yuan, growing by 5.7% year-on-year, with the primary, secondary, and tertiary industries contributing 6.7%, 40.2%, and 53.1% respectively [2] - The province's listed companies are crucial for economic development, focusing on green, low-carbon, and high-quality growth while enhancing technological innovation [2] Performance of Listed Companies - Shandong's listed companies achieved a total revenue of 2.95 trillion yuan in 2024, a year-on-year increase of 4.61%, while net profit was 175.9 billion yuan, down 3.20% [4] - 78.96% of the companies reported profits, which is 5.27 percentage points higher than the national average, indicating better performance despite challenges in traditional industries [4][5] Contribution to Economic Growth - Listed companies in Shandong contributed 29.92% of the province's GDP, with an added value of 705.18 billion yuan, reflecting their significant role in regional economic growth [5] - The labor productivity of listed companies was 483,600 yuan per person, 2.78 times the national average, showcasing their efficiency [5] Innovation and Growth of SMEs - In 2024, 67 companies on the Growth Enterprise Market reported revenues of 177.98 billion yuan, up 15.13%, and net profits of 11.74 billion yuan, up 49.42%, indicating strong growth in innovative SMEs [6] - The total R&D expenditure for these companies was 6.44 billion yuan, a 8.11% increase, highlighting their commitment to innovation [6] Market Capitalization and Value Management - By the end of 2024, the market capitalization of Shandong's listed companies reached 3.63 trillion yuan, a 4.18% increase, ranking seventh nationally [8] - 125 companies conducted share buybacks, totaling 9.568 billion yuan, reflecting a strong commitment to value management [8] Characteristics of Listed Companies - Private listed companies in Shandong accounted for 62.14% of the total, achieving revenues of 838.06 billion yuan, up 4.64%, and net profits of 431.87 billion yuan, up 16.49% [9][10] - Companies with overseas business generated 842.85 billion yuan in foreign income, a year-on-year increase of 8.89%, indicating the importance of international markets [12] Mergers and Acquisitions - In 2024, 13 listed companies in Shandong participated in mergers and acquisitions, with a total transaction value of 38.75 billion yuan, a 3.58-fold increase [14][15] - The trend of state-owned enterprises merging with peers is becoming more common, enhancing market competitiveness [15] Sustainable Development and ESG - Shandong's listed companies showed a 44.34% ESG report disclosure rate, slightly above the national average, indicating a growing recognition of sustainability [16][17] - The average ESG score for Shandong's companies was 5.79, higher than the national average, with two companies scoring above 9.00 [17] Innovation and Digital Transformation - R&D expenses for Shandong's listed companies reached 84.51 billion yuan, a 3.94% increase, with a focus on enhancing innovation capabilities [18] - The digital economy's core companies reported revenues of 330.38 billion yuan, up 27.57%, demonstrating significant growth in this sector [20] Traditional Industry Transformation - Traditional industries in Shandong are undergoing digital and intelligent transformations, with companies like Shandong High-Speed adopting advanced technologies to enhance operational efficiency [23] - The integration of digital and green technologies is seen as essential for fostering new productive forces in traditional sectors [24]

Core Viewpoint - The company has adjusted the maximum repurchase price of its shares from RMB 50.00 per share to RMB 49.5367 per share following the implementation of the 2024 annual profit distribution plan [1][2][3] Summary by Sections 1. Basic Information on Share Repurchase - The company plans to repurchase its shares using its own funds through the Shanghai Stock Exchange, with a total repurchase amount between RMB 100 million and RMB 200 million within 12 months from the board's approval date [1] 2. Reasons for Adjusting the Maximum Repurchase Price - The adjustment is due to the company's decision to distribute a cash dividend of RMB 4.7 per 10 shares to all shareholders, which affects the base for calculating the repurchase price [2][3] 3. Details of the Price Adjustment - The new maximum repurchase price is calculated as follows: (previous maximum price - cash dividend per share) / (1 + change in circulating shares ratio). The cash dividend per share is approximately RMB 0.4633 based on the total shares participating in the distribution [3] 4. Estimated Repurchase Quantity - With the adjusted maximum repurchase price of RMB 49.5367, the company estimates it can repurchase approximately 4.0374 million shares, representing about 1.27% of the total share capital, based on the upper limit of RMB 200 million [4] 5. Other Matters - Other aspects of the share repurchase plan remain unchanged, and the company will adhere to relevant regulations while making repurchase decisions based on market conditions [5]

青岛海尔生物医疗股份有限公司 关于 2024 年年度权益分派实施后调整回购股份 价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 青岛海尔生物医疗股份有限公司（以下简称"公司"）2024 年年度权益 分派实施后，公司以集中竞价交易方式回购股份价格上限由不超过人民币 50.00 元/股（含）调整为不超过人民币 49.5367 元/股（含）。 一、回购股份的基本情况 公司于 2025 年 1 月 13 日召开第三届董事会第四次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》（以下简称"本次回购方案"）， 同意公司以自有资金通过上海证券交易所股票交易系统以集中竞价交易方式回 购公司已发行的部分人民币普通股（A 股）。回购的股份将在未来适宜时机全部 用于员工持股计划或股权激励，回购价格不超过 50 元/股（含），回购资金总额 不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购期限自 公司董事会审议通过本次回购方案之日起 12 个月内。具体内容详见公 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-038 青岛海尔生物医疗股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/14 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 1 1 月 13 | 年 | 月 | 14 | 日~2026 | 年 | 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 1,375,725股 | | | | | | | | 累计已回购股数占总股本比例 | 0.4327% | | ...

Core Viewpoint - The company announced a cash dividend distribution of CNY 0.47 per share for the fiscal year 2024, approved at the annual shareholders' meeting on April 29, 2025 [2][3]. Distribution Plan - The dividend distribution is based on the total share capital after deducting shares held in the company's repurchase account, resulting in a total of 313,425,953 shares eligible for the dividend [4][6]. - The total cash dividend to be distributed amounts to CNY 147,310,197.91 (including tax) [4]. - The cash dividend per share is calculated as approximately CNY 0.4633 after adjustments for the total share capital [6]. Implementation Details - The cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the end of the trading day on the record date [8]. - Shareholders who have not completed designated trading will have their dividends held by the clearing company until the trading is completed [8]. Taxation Information - Individual shareholders holding shares for over one year are exempt from personal income tax on dividends, while those holding for one year or less will have taxes calculated upon the sale of shares [10][11]. - For qualified foreign institutional investors (QFII), a withholding tax of 10% will apply, resulting in a net dividend of CNY 0.423 per share [12].